GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » Cash Ratio

Marvel Biosciences (TSXV:MRVL) Cash Ratio : 0.35 (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Marvel Biosciences's Cash Ratio for the quarter that ended in Jan. 2024 was 0.35.

Marvel Biosciences has a Cash Ratio of 0.35. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Marvel Biosciences's Cash Ratio or its related term are showing as below:

TSXV:MRVL' s Cash Ratio Range Over the Past 10 Years
Min: 0.19   Med: 1   Max: 21.37
Current: 0.35

During the past 4 years, Marvel Biosciences's highest Cash Ratio was 21.37. The lowest was 0.19. And the median was 1.00.

TSXV:MRVL's Cash Ratio is ranked worse than
85.91% of 1505 companies
in the Biotechnology industry
Industry Median: 2.94 vs TSXV:MRVL: 0.35

Marvel Biosciences Cash Ratio Historical Data

The historical data trend for Marvel Biosciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Cash Ratio Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23
Cash Ratio
1.27 21.37 0.83 0.40

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 1.11 0.40 0.19 0.35

Competitive Comparison of Marvel Biosciences's Cash Ratio

For the Biotechnology subindustry, Marvel Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Cash Ratio falls into.



Marvel Biosciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Marvel Biosciences's Cash Ratio for the fiscal year that ended in Jul. 2023 is calculated as:

Cash Ratio (A: Jul. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.557/1.392
=0.40

Marvel Biosciences's Cash Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash Ratio (Q: Jan. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.578/1.666
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marvel Biosciences  (TSXV:MRVL) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Marvel Biosciences Cash Ratio Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Marvel Biosciences (TSXV:MRVL) Business Description

Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Executives
Joseph Roderick Matheson Director, Senior Officer